LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/SI-BONE, Inc. Wins MarCom Award
Company News

SI-BONE, Inc. Wins MarCom Award

December 12, 2014 2 min read Premium comments

Advertisement

SI-BONE, Inc. Wins MarCom Award
SI Joint Patient Community / Courtesy: SI-BONE, Inc.
Secondary

SI-BONE, Inc. must be uncorking the champagne these days…the company has just won the Gold 2014 International MarCom Award for its SI [sacroiliac] Joint Patient Community website (http://sijpc.org/) and an Honorable Mention for the SI Buddy Patient Networking Program. SI-BONE manufactures the iFuse Implant System, a minimally invasive surgical option for sacroiliac joint fusion for conditions (including SI joint dysfunction). Those considering the iFuse procedure can access the SI Joint Patient Community website where they can use the SI-Buddy program to connect with patients who have had already had a successful iFuse surgery.

According to the December 8, 2014 news release, “The MarCom Award is presented by the Association of Marketing and Communications Professionals to companies who have exemplified high standards of excellence and serve as benchmarks for the industry. There were more than 6, 500 entries from throughout the United States, Canada and 15 other countries in the 2014 competition. The SI Joint Patient Community website and SI Buddy Program were entered under the Manufacturers and Advocacy Group categories.”

“Helping patients is the core of everything we do at SI-BONE and we are delighted our team’s initiatives to assist these patients have been recognized, ” said President and Chief Executive Officer Jeffrey Dunn in the news release. “Patients with SI joint dysfunction due to sacroiliac joint disruptions and degenerative sacroiliitis often experience debilitating pain when non-operative care is unsuccessful according to a study that was presented last month at the North American Spine Society and it is very rewarding to be involved in helping these people.”

The news release indicates: “The iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray (TPS) that acts as an interference surface, designed to help decrease implant motion, provide immediate fixation and allow for biological fixation to support long term fusion. The iFuse System is intended for sacroiliac joint fusion for conditions including SI joint dysfunction that is a direct result of SI joint disruptions and degenerative sacroiliitis.”

Dunn told OTW, “The most important and rewarding aspect of our business at SI-BONE is helping patients. We are delighted that our patient web site has been recognized for being terrific i.e., it is very thorough and educational…I guess what that truly means is that it is viewed as being valuable to patients. It is our understanding that patients suffering from sacroiliac joint disruption or degenerative sacroliitis actually spend quite a bit of time and energy researching this area as back pain for many can be debilitating and a very thorough web site like our patient web site can be extremely helpful to these people.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy